                                                                                                                                     II




                                  113TH CONGRESS
                                     1ST SESSION                            S. 504
                                      To amend the Federal Food, Drug, and Cosmetic Act to ensure that valid
                                                      generic drugs may enter the market.




                                              IN THE SENATE OF THE UNITED STATES
                                                                MARCH 7, 2013
                                  Mr. FRANKEN (for himself, Mr. VITTER, Mr. DURBIN, Mrs. SHAHEEN, and
                                      Mr. SANDERS) introduced the following bill; which was read twice and re-
                                      ferred to the Committee on Health, Education, Labor, and Pensions




                                                                            A BILL
                                        To amend the Federal Food, Drug, and Cosmetic Act to
                                         ensure that valid generic drugs may enter the market.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,
                                    3     SECTION 1. SHORT TITLE.
                                    4              This Act may be cited as the ‘‘Fair And Immediate
                                    5 Release of Generic Drugs Act’’ or the ‘‘FAIR Generics
                                    6 Act’’.
                                    7     SEC. 2. 180-DAY EXCLUSIVITY PERIOD AMENDMENTS RE-
                                    8                             GARDING FIRST APPLICANT STATUS.
                                    9              (a) AMENDMENTS                      TO     FEDERAL FOOD, DRUG,                  AND
                                  10 COSMETIC ACT.—                                        2
                                    1                        (1) IN       GENERAL.—Section                       505(j)(5)(B) of the
                                    2              Federal Food, Drug, and Cosmetic Act (21 U.S.C.
                                    3              355(j)(5)(B)) is amended—
                                    4                                 (A) in clause (iv)(II)—
                                    5                                        (i) by striking item (bb); and
                                    6                                        (ii) by redesignating items (cc) and
                                    7                                 (dd) as items (bb) and (cc), respectively;
                                    8                                 and
                                    9                                 (B) by adding at the end the following:
                                  10               ‘‘(v) FIRST APPLICANT DEFINED.—As used in this
                                  11 subsection, the term ‘first applicant’ means an applicant—
                                  12                         ‘‘(I)(aa) that, on the first day on which a sub-
                                  13               stantially complete application containing a certifi-
                                  14               cation described in paragraph (2)(A)(vii)(IV) is sub-
                                  15               mitted for approval of a drug, submits a substan-
                                  16               tially complete application that contains and lawfully
                                  17               maintains a certification described in paragraph
                                  18               (2)(A)(vii)(IV) for the drug; and
                                  19                         ‘‘(bb) that has not entered into a disqualifying
                                  20               agreement described under clause (vii)(II); or
                                  21                         ‘‘(II)(aa) for the drug that is not described in
                                  22               subclause (I) and that, with respect to the applicant
                                  23               and drug, each requirement described in clause (vi)
                                  24               is satisfied; and





                                              •S 504 IS

                                                                                             3
                                    1                        ‘‘(bb) that has not entered into a disqualifying
                                    2              agreement described under clause (vii)(II).
                                    3              ‘‘(vi) REQUIREMENT.—The requirements described in
                                    4 this clause are the following:
                                    5                        ‘‘(I) The applicant described in clause (v)(II)
                                    6              submitted and lawfully maintains a certification de-
                                    7              scribed in paragraph (2)(A)(vii)(IV) or a statement
                                    8              described in paragraph (2)(A)(viii) for each unex-
                                    9              pired patent for which a first applicant described in
                                  10               clause (v)(I) had submitted a certification described
                                  11               in paragraph (2)(A)(vii)(IV) on the first day on
                                  12               which a substantially complete application contain-
                                  13               ing such a certification was submitted.
                                  14                         ‘‘(II) With regard to each such unexpired pat-
                                  15               ent for which the applicant described in clause
                                  16               (v)(II) submitted a certification described in para-
                                  17               graph (2)(A)(vii)(IV), no action for patent infringe-
                                  18               ment was brought against such applicant within the
                                  19               45-day period specified in paragraph (5)(B)(iii); or
                                  20               if an action was brought within such time period,
                                  21               such an action was withdrawn or dismissed by a
                                  22               court (including a district court) without a decision
                                  23               that the patent was valid and infringed; or if an ac-
                                  24               tion was brought within such time period and was




                                  25               not withdrawn or so dismissed, such applicant has
                                              •S 504 IS

                                                                                             4
                                    1              obtained the decision of a court (including a district
                                    2              court) that the patent is invalid or not infringed (in-
                                    3              cluding any substantive determination that there is
                                    4              no cause of action for patent infringement or inva-
                                    5              lidity, and including a settlement order or consent
                                    6              decree signed and entered by the court stating that
                                    7              the patent is invalid or not infringed).
                                    8                        ‘‘(III) If an applicant described in clause (v)(I)
                                    9              has begun commercial marketing of such drug, the
                                  10               applicant described in clause (v)(II) does not begin
                                  11               commercial marketing of such drug until the date
                                  12               that is 30 days after the date on which the applicant
                                  13               described in clause (v)(I) began such commercial
                                  14               marketing.’’.
                                  15                         (2)          CONFORMING                       AMENDMENT.—Section
                                  16               505(j)(5)(D)(i)(IV)                       of     such           Act        (21   U.S.C.
                                  17               355(j)(5)(D)(i)(IV)) is amended by striking ‘‘The
                                  18               first applicant’’ and inserting ‘‘The first applicant,
                                  19               as defined in subparagraph (B)(v)(I),’’.
                                  20               (b) APPLICABILITY.—The amendments made by sub-
                                  21 section (a) shall apply only with respect to an application
                                  22 filed under section 505(j) of the Federal Food, Drug, and
                                  23 Cosmetic Act (21 U.S.C. 355(j)) to which the amendments
                                  24 made by section 1102(a) of the Medicare Prescription





                                              •S 504 IS

                                                                                             5
                                    1 Drug, Improvement, and Modernization Act of 2003 (Pub-
                                    2 lic Law 108–173) apply.
                                    3     SEC. 3. 180-DAY EXCLUSIVITY PERIOD AMENDMENTS RE-
                                    4                             GARDING AGREEMENTS TO DEFER COMMER-
                                    5                             CIAL MARKETING.

                                    6              (a) AMENDMENTS                      TO        FEDERAL FOOD, DRUG,                 AND
                                    7 COSMETIC ACT.—
                                    8                        (1) LIMITATIONS                     ON AGREEMENTS TO DEFER
                                    9              COMMERCIAL                          MARKETING                            DATE.—Section
                                  10               505(j)(5)(B) of the Federal Food, Drug, and Cos-
                                  11               metic Act (21 U.S.C. 355(j)(5)(B)), as amended by
                                  12               section 2, is further amended by adding at the end
                                  13               the following:
                                  14                         ‘‘(vii) AGREEMENT                     BY FIRST APPLICANT TO
                                  15               DEFER COMMERCIAL MARKETING; LIMITATION ON
                                  16               ACCELERATION OF DEFERRED COMMERCIAL MAR-
                                  17               KETING DATE.—
                                  18                                  ‘‘(I) AGREEMENT                    TO DEFER APPROVAL OR
                                  19                         COMMERCIAL                MARKETING                  DATE.—An         agree-
                                  20                         ment described in this subclause is an agree-
                                  21                         ment between a first applicant and the holder
                                  22                         of the application for the listed drug or an
                                  23                         owner of one or more of the patents as to which
                                  24                         any applicant submitted a certification quali-




                                  25                         fying such applicant for the 180-day exclusivity
                                              •S 504 IS

                                                                                             6
                                    1                        period whereby that applicant agrees, directly
                                    2                        or indirectly, (aa) not to seek an approval of its
                                    3                        application that is made effective on the earliest
                                    4                        possible date under this subparagraph, subpara-
                                    5                        graph (F) of this paragraph, section 505A, or
                                    6                        section 527, (bb) not to begin the commercial
                                    7                        marketing of its drug on the earliest possible
                                    8                        date after receiving an approval of its applica-
                                    9                        tion that is made effective under this subpara-
                                  10                         graph, subparagraph (F) of this paragraph, sec-
                                  11                         tion 505A, or section 527, or (cc) to both items
                                  12                         (aa) and (bb).
                                  13                                  ‘‘(II) AGREEMENT                   THAT DISQUALIFIES AP-
                                  14                         PLICANT FROM FIRST APPLICANT STATUS.—An
                                  15                         agreement described in this subclause is an
                                  16                         agreement between an applicant and the holder
                                  17                         of the application for the listed drug or an
                                  18                         owner of one or more of the patents as to which
                                  19                         any applicant submitted a certification quali-
                                  20                         fying such applicant for the 180-day exclusivity
                                  21                         period whereby that applicant agrees, directly
                                  22                         or indirectly, not to seek an approval of its ap-
                                  23                         plication or not to begin the commercial mar-
                                  24                         keting of its drug until a date that is after the




                                  25                         expiration of the 180-day exclusivity period
                                              •S 504 IS

                                                                                             7
                                    1                        awarded to another applicant with respect to
                                    2                        such drug (without regard to whether such 180-
                                    3                        day exclusivity period is awarded before or after
                                    4                        the date of the agreement).
                                    5                        ‘‘(viii) LIMITATION                  ON ACCELERATION.—If              an
                                    6              agreement described in clause (vii)(I) includes more
                                    7              than 1 possible date when an applicant may seek an
                                    8              approval of its application or begin the commercial
                                    9              marketing of its drug—
                                  10                                  ‘‘(I) the applicant may seek an approval of
                                  11                         its application or begin such commercial mar-
                                  12                         keting on the date that is the earlier of—
                                  13                                         ‘‘(aa) the latest date set forth in the
                                  14                                  agreement on which that applicant can re-
                                  15                                  ceive an approval that is made effective
                                  16                                  under this subparagraph, subparagraph
                                  17                                  (F) of this paragraph, section 505A, or
                                  18                                  section 527, or begin the commercial mar-
                                  19                                  keting of such drug, without regard to any
                                  20                                  other provision of such agreement pursu-
                                  21                                  ant to which the commercial marketing
                                  22                                  could begin on an earlier date; or
                                  23                                         ‘‘(bb) 180 days after another first ap-
                                  24                                  plicant begins commercial marketing of




                                  25                                  such drug; and
                                              •S 504 IS

                                                                                             8
                                    1                                 ‘‘(II) the latest date set forth in the agree-
                                    2                        ment on which that applicant can receive an ap-
                                    3                        proval that is made effective under this sub-
                                    4                        paragraph, subparagraph (F) of this paragraph,
                                    5                        section 505A, or section 527, or begin the com-
                                    6                        mercial marketing of such drug, without regard
                                    7                        to any other provision of such agreement pursu-
                                    8                        ant to which commercial marketing could begin
                                    9                        on an earlier date, shall be the date used to de-
                                  10                         termine whether an applicant is disqualified
                                  11                         from first applicant status pursuant to clause
                                  12                         (vii)(II).’’.
                                  13                         (2) NOTIFICATION                    OF FDA.—Section                   505(j) of
                                  14               such Act (21 U.S.C. 355(j)) is amended by adding
                                  15               at the end the following:
                                  16               ‘‘(11)(A) The holder of an abbreviated application
                                  17 under this subsection shall submit to the Secretary a noti-
                                  18 fication that includes—
                                  19                         ‘‘(i)(I) the text of any agreement entered into
                                  20               by        such          holder            described             under           paragraph
                                  21               (5)(B)(vii)(I); or
                                  22                         ‘‘(II) if such an agreement has not been re-
                                  23               duced to text, a written detailed description of such
                                  24               agreement that is sufficient to disclose all the terms




                                  25               and conditions of the agreement; and
                                              •S 504 IS

                                                                                             9
                                    1                        ‘‘(ii) the text, or a written detailed description
                                    2              in the event of an agreement that has not been re-
                                    3              duced to text, of any other agreements that are con-
                                    4              tingent upon, provide a contingent condition for, or
                                    5              are otherwise related to an agreement described in
                                    6              clause (i).
                                    7              ‘‘(B) The notification described under subparagraph
                                    8 (A) shall be submitted not later than 10 business days
                                    9 after execution of the agreement described in subpara-
                                  10 graph (A)(i). Such notification is in addition to any notifi-
                                  11 cation required under section 1112 of the Medicare Pre-
                                  12 scription Drug, Improvement, and Modernization Act of
                                  13 2003.
                                  14               ‘‘(C) Any information or documentary material filed
                                  15 with the Secretary pursuant to this paragraph shall be ex-
                                  16 empt from disclosure under section 552 of title 5, United
                                  17 States Code, and no such information or documentary ma-
                                  18 terial may be made public, except as may be relevant to
                                  19 any administrative or judicial action or proceeding. Noth-
                                  20 ing in this paragraph is intended to prevent disclosure to
                                  21 either body of the Congress or to any duly authorized com-
                                  22 mittee or subcommittee of the Congress.’’.
                                  23                         (3) PROHIBITED                  ACTS.—Section                  301(e) of such
                                  24               Act (21 U.S.C. 331(e)) is amended by striking ‘‘505





                                  25               (i) or (k)’’ and inserting ‘‘505 (i), (j)(11), or (k)’’.


                                              •S 504 IS

                                                                                         10
                                    1              (b) INFRINGEMENT                      OF     PATENT.—Section 271(e) of
                                    2 title 35, United States Code, is amended by adding at the
                                    3 end the following:
                                    4              ‘‘(7) The exclusive remedy under this section for an
                                    5 infringement of a patent for which the Secretary of Health
                                    6 and Human Services has published information pursuant
                                    7 to subsection (b)(1) or (c)(2) of section 505 of the Federal
                                    8 Food, Drug, and Cosmetic Act shall be an action brought
                                    9 under this subsection within the 45-day period described
                                  10 in subsection (j)(5)(B)(iii) or (c)(3)(C) of section 505 of
                                  11 the Federal Food, Drug, and Cosmetic Act.’’.
                                  12               (c) APPLICABILITY.—
                                  13                         (1) LIMITATIONS                    ON ACCELERATION OF DE-
                                  14               FERRED              COMMERCIAL                   MARKETING                  DATE.—The
                                  15               amendment made by subsection (a)(1) shall apply
                                  16               only with respect to—
                                  17                                  (A) an application filed under section
                                  18                         505(j) of the Federal Food, Drug, and Cos-
                                  19                         metic Act (21 U.S.C. 355(j)) to which the
                                  20                         amendments made by section 1102(a) of the
                                  21                         Medicare Prescription Drug, Improvement, and
                                  22                         Modernization Act of 2003 (Public Law 108–
                                  23                         173) apply; and
                                  24                                  (B) an agreement described under section




                                  25                         505(j)(5)(B)(vii)(I) of the Federal Food, Drug,
                                              •S 504 IS

                                                                                         11
                                    1                        and Cosmetic Act (as added by subsection
                                    2                        (a)(1)) executed after the date of enactment of
                                    3                        this Act.
                                    4                        (2) NOTIFICATION                    OF FDA.—The                   amendments
                                    5              made by paragraphs (2) and (3) of subsection (a)
                                    6              shall apply only with respect to an agreement de-
                                    7              scribed under section 505(j)(5)(B)(vii)(I) of the
                                    8              Federal Food, Drug, and Cosmetic Act (as added by
                                    9              subsection (a)(1)) executed after the date of enact-
                                  10               ment of this Act.
                                              •S 504 IS                                    Æ
